Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
-
Randomized Controlled Trial
Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.
To investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD). ⋯ Weekly cholecalciferol supplementation appears to be an effective treatment to correct vitamin D status in patients with CKD.
-
To describe a patient with excess urinary thyroxine (T4) excretion and worsening of preexisting hypothyroidism in the setting of nephrotic syndrome and to determine whether excess urinary T4 excretion is present in other patients with proteinuria. ⋯ In the patient described, urinary T4 loss due to proteinuria and nephrotic syndrome resulted in a severe exacerbation of underlying hypothyroidism.
-
Case Reports
Ovarian hilus-cell hyperplasia and high serum testosterone in a patient with postmenopausal virilization.
To describe a woman with postmenopausal virilization and hirsutism caused by hilus-cell hyperplasia. ⋯ In the differential diagnosis of postmenopausal virilization, hilus-cell hyperplasia, although rare, should be considered.
-
To review the clinical manifestations and current treatment options for diabetic neuropathies, one of the most common complications of diabetes mellitus. ⋯ Symptomatic therapy has become available and newer and better treatment modalities, based on etiologic factors, are being explored with potential for clinically significant reduction of morbidity and mortality. Preventive strategies and patient and physician education still remain key factors in reducing complication rates and mortality.
-
Review
Current controversy related to glucocorticoid and insulin therapy in the intensive care unit.
To review the controversy related to the widespread use of intensive insulin treatment (IIT) to maintain normoglycemia and of glucocorticoid replacement therapy in patients with sepsis in the intensive care unit (ICU). ⋯ Endocrine therapy in the ICU is entering a new era. Controversies remain related to glucocorticoid and insulin therapy even as interest in new, and old, endocrine therapies is being revived.